Vertex and Covid-19 spell the end for Savara's CF program
It’s a tough market for cystic fibrosis these days. Just ask Savara.
Two years ago, the Austin-based biotech designed and launched a trial to test …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
